(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel 1 Feb Written by Carla Aguilera Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, Castellani R, Lynch T, Shulkin B, Drobics M, Staudenherz A, Ladenstein R. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):234-241. doi: 10.1007/s00259-016-3516-0. Epub 2016 Sep 24. PMID: 27663238; PMCID: PMC5214990. 2017 Carla Aguilera Previous Previous Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma … Next Next Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel 1 Feb Written by Carla Aguilera Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, Castellani R, Lynch T, Shulkin B, Drobics M, Staudenherz A, Ladenstein R. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):234-241. doi: 10.1007/s00259-016-3516-0. Epub 2016 Sep 24. PMID: 27663238; PMCID: PMC5214990. 2017 Carla Aguilera
